Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04781400
Other study ID # 448/2020
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 8, 2021
Est. completion date May 13, 2022

Study information

Verified date August 2022
Source Desmond Tutu HIV Foundation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Sub Saharan Africa is home to only 12% of the population, but accounts for approximately 70% of the global burden of HIV infection and 84% of infections among young people aged 10-24 years. South Africa, which currently has the largest SARS-CoV-2 pandemic in SSA, also has the largest HIV epidemic globally. Access and service delivery barriers to engaging in HIV care have contributed to estimates that only 49% of adolescents (aged 10-19 years) entering care from 2005-2016 have initiated antiretroviral therapy (ART). In response to the SARS-CoV-2 pandemic the South African government has implemented national lock-down orders that we predict will further inhibit treatment engagement among young people. Research is needed to identify best practices for safely retaining young people living with HIV (YPLWH) in care during COVID-19.


Description:

The primary objectives of this study are to examine the feasibility, acceptability, and preliminary efficacy of a remote service delivery model for young people living with HIV aged 13-24 years that will include a monthly service needs assessment and optional delivery of HIV treatment services. YPLWH will also be randomized to receive (or not receive) mobile check-ins from study staff and access to two-way messaging capabilities to obtain continuous support for adherence to ART and COVID-19 prevention guidelines. Investigators will also assess the impact of the COVID-19 lock-down orders on multi-level factors (individual, socio-behavioral, structural) over time among young people aged 13-24 years living with HIV (same cohort as above) and without HIV. Particular focus will be given to experience and perpetration of gender based violence. In addition, investigators will assess the impact of multi-level factors on compliance with COVID-19 prevention guidelines, health service utilization, and engagement in HIV care (YPLWH only). Findings will be examined overall and stratified by HIV status and gender. Ultimately investigators hope to: (i) determine whether a remote service delivery model will help retain young people in HIV care and (ii) Inform the development of an intervention for young people in the study communities who may be experiencing GBV and associated outcomes in the wake of the pandemic.


Recruitment information / eligibility

Status Completed
Enrollment 536
Est. completion date May 13, 2022
Est. primary completion date May 13, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 13 Years to 24 Years
Eligibility Inclusion Criteria: Young people living with HIV who meet all of the following criteria will be eligible for inclusion into this study: 1. Speak isiXhosa and or English, residing in the Khayelitsha /Mitchell's Plain area 2. 13-24 years (inclusive) 3. Willing and able to provide informed telephonic or in person consent 4. Initiated ART at one of two health facilities and are currently in HIV care (i.e. received ART and had a viral load measurement in the past six months) 5. Regular access to a mobile phone with SMS or WhatsApp capacity (can include the phone of a parent/caregiver if the participant is <18 years or does not have their own phone) Young people living without HIV from the same communities who meet all of the following criteria will be eligible for inclusion into this study: 1. Speak isiXhosa and or English, residing in the Khayelitsha / Mitchell's Plain area 2. 13-24 years (inclusive) 3. Willing and able to provide informed telephonic or in person consent 4. Has not previously tested positive for HIV and self-reports being HIV negative (i.e., not known to be living with HIV). 5. Regular access to a mobile phone (can include the phone of a parent/caregiver if the participant is <18 years or does not have their own phone) Exclusion Criteria: Young people living with HIV who meet any of the following criteria will be excluded from this study: 1. Not 13-24 years (inclusive) 2. Unwilling or unable to provide informed telephonic or in person consent 3. Not currently receiving ART care at a Desmond Tutu Health Foundation health facility 4. No regular access to a mobile phone with SMS or WhatsApp capacity 5. Planning to relocate in the next 6 months Young people living without HIV from the same communities who meet any of the following criteria will be excluded this study: 1. Not 13-24 years (inclusive) 2. Unwilling or unable to provide informed telephonic or in person consent 3. Previously tested positive for HIV or is known to be living with HIV 4. No regular access to a mobile phone 5. Planning to relocate in the next 6 months

Study Design


Intervention

Behavioral:
Mobile phone support
Mobile phone support (SMS)
Remote service delivery model
ART treatment delivery via a courier service

Locations

Country Name City State
South Africa Gugulethu Community Health Centre Cape Town Western Cape

Sponsors (5)

Lead Sponsor Collaborator
Desmond Tutu HIV Foundation Karolinska Institutet, University of KwaZulu, University of North Carolina, Chapel Hill, ViiV Healthcare

Country where clinical trial is conducted

South Africa, 

Outcome

Type Measure Description Time frame Safety issue
Primary Acceptability of a remote service delivery and mobile support intervention assessed by the number of participants opting in to receive courier delivery of ART. Program evaluation of a remote service delivery including mobile support intervention and courier delivery of ART amongst young people living with HIV. 6 months
Primary Engagement in HIV care assessed by serial measurements of HIV Viral load. Measurement of HIV viral load will be done at baseline, month three and month six to determine whether adherence to ART has been met (decrease or increase in HIV Viral load) 6 months
Primary Changes in Gender Based Violence (GBV) incidence as a result of COVID lock-down measures as assessed by self reported surveys. Investigate changes in self-reported GBV experience or perpetration, and other individual, social-behavioral, and structural factors that have been impacted by COVID-19 lock down orders. 6 months
Secondary Incidence of COVID-19 infection by assessing participant IgG antibody levels. Retrospective COVID-19 antibody testing at baseline and month 6 months
Secondary Qualitative themes assessed from in-depth individual interview data Qualitative interviews will be used to inform intervention utility and the development of an intervention to reduce GBV 6 months
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2